The supplement industry in Europe is undergoing a significant transformation, with regulatory updates bringing about a wave of changes. These updates have far-reaching implications, impacting everything from product formulations to packaging strategies and compliance plans. As an industry insider, I find it fascinating to witness how these regulatory shifts are reshaping the landscape.
Ingredients Under Scrutiny
Several supplement ingredients are currently under the regulatory microscope. Berberine, hydroxycitric acid (HCA), and monacolin K from red yeast rice are facing formal safety reviews, with potential bans or restrictions looming. Meanwhile, ashwagandha, CBD, and caffeine are also attracting regulatory attention, though formal safety assessments have yet to commence. It's a delicate balance for manufacturers, as they navigate the fine line between innovation and compliance.
One positive development is the favorable safety opinion received by β-NMN (nicotinamide mononucleotide) from EFSA, bringing this novel food closer to EU approval. This highlights the importance of thorough safety assessments and the potential for innovative ingredients to gain regulatory acceptance.
Novel Foods and Health Claims
The European Commission's Novel Food Catalogue is a dynamic list, regularly updated to reflect the regulatory status of ingredients based on their history of consumption in the EU. CBD, in particular, has had a tumultuous year, with multiple novel food rejections. This includes isolated and synthetic cannabidiol, as well as tinctures and oils from Cannabis sativa. EFSA has also rejected claims for broad-spectrum CBD extracts and distillates from hemp.
On the other hand, pomegranate extract and whey protein concentrate with alpha-lactalbumin have been classified as non-novel, ensuring their continued availability in the European market. These updates demonstrate the intricate process of evaluating and authorizing novel foods, which can have a significant impact on the industry.
Health claim updates are also worth noting. So far this year, only one ingredient, oat-beta glucans, has received a positive health claim opinion from EFSA. This highlights the rigorous evaluation process and the high bar for substantiating health claims.
QPS List and Microbial Innovation
The QPS (Qualified Presumption of Safety) list is a positive development for the industry, providing a streamlined approach to safety assessments for microbes. EFSA evaluates these microbes based on their taxonomic identity, relevant knowledge, and safety concerns. The list helps facilitate faster market authorization for ingredients included on it. This approach encourages microbial innovation and the development of safe and sustainable ingredients.
New Legislative Developments
The supplement industry is navigating several new legislative developments, including the setting of MPLS (Maximum Permitted Levels) for vitamins and minerals in supplements and fortified foods. This process involves a call for evidence and a public consultation, with the final legal act scheduled for 2028.
The industry is also grappling with the new Packaging and Packaging Waste Regulation (PPWR), which includes bans on PFAS (per- and polyfluoroalkyl substances) in food-contact packaging and requirements for packaging declarations of conformity. The supplement sector is concerned about the tight timeline for implementing these changes and has called for a temporary derogation.
Additionally, the new UK-EU Sanitary and Phytosanitary (SPS) agreement, expected to come into force in 2027, will require the UK to align its standards with the EU's rules, impacting ingredient suppliers, manufacturers, and retailers.
These regulatory updates showcase the intricate dance between innovation and compliance in the supplement industry. As an industry observer, I find it intriguing to see how these changes will shape the future of supplements in Europe and beyond.
